Abstract
Over the last 50 years, the concept of stress has evolved significantly, and our understanding of the underlying neurobiology has expanded dramatically. Rather than consider stress biology to be relevant only under unusual and threatening conditions, we conceive of it as an ongoing, adaptive process of assessing the environment, coping with it, and enabling the individual to anticipate and deal with future challenges. Though much remains to be discovered, the fundamental neurocircuitry that underlies these processes has been broadly delineated, key molecular players have been identified, and the impact of this system on neuroplasticity has been well established. More recently, we have come to appreciate the critical interaction between the brain and the rest of the body as it pertains to stress responsiveness. Importantly, this system can become overloaded due to ongoing environmental demands on the individual, be they physical, physiological, or psychosocial. The impact of this overload is deleterious to brain health, and it results in vulnerability to a range of brain disorders, including major depression and cognitive deficits. Thus, stress biology is one of the best understood systems in affective neuroscience and is an ideal target for addressing the pathophysiology of many brain-related diseases. The story we present began with the discovery of glucocorticoid receptors in hippocampus and has extended to other brain regions in both animal models and the human brain with the further discovery of structural and functional adaptive plasticity in response to stressful and other experiences.
Introduction
The concept of stress permeates our culture at multiple levels. In normal parlance, it indicates a demanding, sometimes overwhelming, state, accompanied with negative emotions. For many scientists, the word stress is associated with Selye's characterization of a “fight-or-flight” response to a threat, that is, an acute, adaptive response to an environmental stimulus. But over the last 50 years, science in general and neuroscience in particular have expanded these ideas along many dimensions. We conceive of biological responses to stress biology not in terms of engendering a negative state, but as a typically positive, adaptive set of mechanisms that enhance survival. As importantly, we have come to appreciate that stress biology is not simply an “emergency system,” but rather an ongoing process: the body and brain adapt to our daily experiences whether we call them stressful or not. These experiences include our adherence or lack thereof to our circadian cycle, whether we are lonely or socially interactive, our daily physical activity, and whether we live in a crowded, noisy, dangerous environment or have access to green space and some sources of peace and tranquility. Given this, we recognize that chronic, uncontrollable stress is not only negative, but can become toxic, harming physical and psychiatric health. Thus, we have come to differentiate “good stress” and “bad stress” (McEwen, 2019; Spencer-Segal and Akil, 2019).
This view of the biology of stress has led to the concept of allostasis and allostatic load/overload (Fig. 1). Allostasis refers to the active process of adapting and maintaining stability (or homeostasis) through the production of mediators, like cortisol, that promote adaptation. However, if the perturbations in the environment are unrelenting, the equilibrium set point needs to be altered to a “new normal,” and this can be costly to the organism. “Allostatic load refers to the price the body pays for being forced to adapt to adverse psychosocial or physical situations” (McEwen, 2000). These concepts highlight the protective effects of the multiple, nonlinear mediators of adaptation, as well as the damage that occurs when the same mediators are overused or dysregulated.
This broad and evolving concept of stress biology places the brain at the center of the response to experience, as it integrates information about the internal and external environment and shapes responses at both the systemic and behavioral levels (McEwen, 1998). The brain is a vulnerable organ that can be damaged by toxic stress, but it is also capable of adaptive plasticity and resilience. This plasticity exists throughout life, with critical periods such as early life and adolescence when it is particularly evident. The neural adaptations to the environment are cumulative across the life span, and brain function at any later point in life is the result of experiences and epigenetic alterations that take place before conception, during gestation, and throughout postnatal development.
This reconceptualization of stress is also informed by an impressive body of knowledge about its biological underpinnings at the molecular, circuit, and endocrine levels. The landmark discoveries of key molecular players coupled with the characterization of underlying neural circuitry provide an exciting framework for understanding a basic, shared function in all organisms as they cope and adapt to their environment. As importantly, since psychiatric, addictive, and many neurological disorders are often triggered or aggravated by life stressors, stress biology represents a springboard for translational research across the range of brain disorders.
In this article, we summarize what we believe are the key ideas and findings that have helped to shape the field of stress neurobiology over the past 50 years. While the review is not intended to be exhaustive, we fully recognize numerous and critical contributions by other laboratories, many of whom are referenced in text or tables.
The major neural and molecular elements of the stress system
The cascade of events that leads to an adaptive stress response is well delineated (Fig. 2). Acutely, a novel, unexpected, or threatening stimulus, either within the organism or in its environment, triggers neural responses in the brain that are appropriate to that stimulus (e.g., in the auditory system if it was a loud noise). Beyond the sensory encoding is an affective response that labels the stimulus as salient, relevant, sometimes positive, and sometimes threatening. The final common path for this affective response leads to the paraventricular nucleus of the hypothalamus (PVN), where it activates the release of corticotropin-releasing factor [CRF; or corticotropin-releasing hormone (CRH)] as well as arginine vasopressin. These neuropeptides then stimulate the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary, leading to the synthesis and release of glucocorticoids from the adrenal cortex. These glucocorticoids have a wide range of actions throughout the body (including energy balance and glucose utilization, as indicated by their name).
Fifty years ago, around the time of the founding of the Society for Neuroscience, the concept of a hypothalamo–pituitary–adrenal (HPA) axis existed in neuroendocrinology, but the emphasis was on the role of putative releasing factors in the hypothalamus with little focus on other brain areas. There had been a long-standing quest for a molecular understanding of all the key players in the stress axis. Pioneering work by (Li et al., 1942, 1955) led to the isolation of ACTH from the pituitary gland (Turecki and Meaney, 2016). By the 1970s, elegant biochemical work showed that ACTH derived from a complex molecular precursor, which encoded not only ACTH, but also the opioid β-endorphin and α- and β-melanocyte stimulating hormone (Mains et al., 1977; Roberts and Herbert, 1977). Forty years ago, the full ACTH/endorphin precursor was cloned and came to be known as proopiomelancortin (POMC; Nakanishi et al., 1979). POMC undergoes ordered post-translational processing in the anterior pituitary to release the stress hormone ACTH into the bloodstream along with β-lipotropin. POMC was the first gene whose expression was demonstrated in the brain using in situ hybridization (Gee et al., 1983). It was clear even then that brain POMC serves functions distinct from pituitary POMC (Akil et al., 1984). The hypothalamic factors that release ACTH from the anterior pituitary were also the subject of an intense search. While evidence of various activities emerged in the 1960s (Schally et al., 1960), it was not till 1981 that Vale et al. (1981) isolated CRF and demonstrated that it releases ACTH.
The gateway to a broader neural focus on the brain in the study of stress began with the discovery in 1968 of putative receptors for adrenal steroids in the hippocampal formation. This work used 3H-corticosterone in adrenalectomized rats, and later in rhesus monkeys, to visualize the binding of this steroid hormone in the nervous system (McEwen et al., 1968). The discovery of these hippocampal glucocorticoid binding sites extended hormone action beyond the hypothalamus to a brain region that was already known to be involved in learning and memory, setting the stage for the much broader conceptualization summarized above. This presaged research that showed the brain to be the target of numerous other hormones, including sex, thyroid, and metabolic hormones, such as insulin and ghrelin (McEwen, 2007). However, >25 years would pass before the molecular nature of these glucocorticoid binding sites was identified.
It is now known that the impact of glucocorticoids on the brain (corticosterone in rodents and cortisol in humans) is mediated via two main receptors, the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR). Both are ligand-activated transcription factors (i.e., the binding of steroids modifies their transcriptional activity), leading to either positive or negative regulation of the expression of their target genes. The cloning of the GR took place in the early 1980s (Miesfeld et al., 1984; Hollenberg et al., 1985). This was followed shortly thereafter by the cloning of MR (Arriza et al., 1987). MR was subsequently cloned directly from a hippocampal library (Patel et al., 1989), and its anatomical expression in the brain was defined in direct comparison to GR, showing their close coexpression in many brain regions (Herman et al., 1989). MR has higher affinity for glucocorticoids than GR, and in the brain it functions coordinately with GR in the control of stress and its impact on affective and cognitive function (Joëls and de Kloet, 2017). While GR has been implicated in stress negative feedback, MR has been implicated in the modulation of basal glucocorticoid circadian rhythm and pulsatile secretion of ACTH into the blood (Bradbury et al., 1991; Gjerstad et al., 2018).
A healthy response to an acute stressor requires both a rapid and vigorous activation of a response that leads to the synthesis and release of glucocorticoids, as described above. But it also requires an effective means of terminating that stress response to avoid overwhelming the system with the powerful actions of the stress hormones. This termination is based on a negative feedback mechanism that is mediated at many levels—the pituitary, the PVN, and, especially, the hippocampus, which is rich in GR but in which the diurnal variation of glucocorticoids primes the system to turn off the HPA response rather than acting like a thermostat (Akana et al., 1988; Jacobson et al., 1988). The neural circuit that connects the hippocampus to the PVN and is critical for the termination of the stress response was first delineated by the laboratory of S. J. Watson (Cullinan et al., 1993; Herman et al., 1995). It involves a bisynaptic pathway from the hippocampus to the PVN with a relay station in the bed nucleus of the stria terminalis. Lesions along this pathway lead to overexpression of CRH mRNA in the PVN and long durations of the stress response. As will be described below, environmental and psychosocial factors that disrupt the hippocampus can also lead to excessive levels of glucocorticoids, which can in turn further damage the hippocampus.
How brain and body systems continually interact for brain health and disease
Identification of “stress hormone” receptors in hippocampus led in multiple other directions. In addition to hippocampus, such receptors were found to be expressed and act in other brain regions involved in cognition and emotion, such as amygdala and prefrontal cortex (Figs. 1, 2), and acute and chronic stressors were found to cause adaptive structural plasticity within interconnected brain regions. Adaptive plasticity is a term that describes how chronic stress can remodel the brain in a neuroprotective manner, causing retraction of dendrites and loss of synapses in areas that are highly stress sensitive, such as hippocampus, medial amygdala, and medial prefrontal cortex, while at the same time causing the expansion of dendrites and new synapses in other areas such as basolateral amygdala and orbitofrontal cortex (Price and Drevets, 2010; McEwen and Morrison, 2013; Chattarji et al., 2015; Lau et al., 2017). These morphological changes subserve alterations in behavioral, autonomic, and neuroendocrine functions that are appropriate for coping with the ongoing stressor (e.g., ongoing threat or danger).
Based on animal models, numerous systemic and neural mediators contribute to adaptive plasticity, including insulin; IGF-1 from liver (Trejo et al., 2001); a muscle hormone, cathepsin B (Moon and van Praag, 2014); and the bone hormone osteocalcin (Khrimian et al., 2017), all of which gain access to the brain and act upon their respective receptors to induce protective morphological changes. Similarly, leptin, which is expressed in hippocampus but can also reach the hippocampus from the blood, facilitates neurogenesis and has antioxidant neuroprotective effects (Yook et al., 2019). Table 1 summarizes the range of mediators, including signaling molecules locally produced in brain, such as brain-derived neurotrophic factor (BDNF), FGF2 (fibroblast growth factor 2), endocannabinoids, and CRF, as well as cellular processes at the cell nucleus, cytoskeleton, and cell surface.
When conditions improve, the healthy brain exhibits resilience and recovers, even though this is not a true reversal, as some of the morphological changes persist and may even serve to buffer against further stress (Goldwater et al., 2009). However, if stress-related demands continue, then the brain can “get stuck,” that is, fail to further adapt structurally or functionally even when external stressors diminish, leading to pathological conditions where external intervention is needed (Figs. 1, 3). Examples of such conditions are clinical anxiety or major depression, which may begin with an appropriate response to a stressful event but become maladaptive when they persist and become chronic. Immune cells can gain access to a brain vulnerable to social stress (Menard et al., 2017), and the same mediators implicated in adaptive plasticity, including both glucocorticoids and excitatory amino acid transmitters, can cause permanent damage. This demonstrates the concept that there exists an inverted U-shaped function for optimal actions of glucocorticoids and other signaling molecules in response to stress (Fig. 3).
Experience and the epigenetic life course
The actions of hormones, and of experiences in general, result in epigenetic regulation of genetic information leading to individual differences even among identical twins. The epigenetic life-course perspective emphasizes that life is a one-way street where influences even before conception, as well as during prenatal development, childhood, adolescence, and onward determine trajectories of health or risk for disease. The idea of a continually unfolding activity of gene expression is exemplified in the pattern of hippocampal responses to stressors, wherein a given novel stressor produces some changes in gene expression that are shared across individuals, but also many changes that differ as a function of different histories of stress (Gray et al., 2014). While it is impossible to erase the biological consequences of experience, an individual's trajectory can be modified by additional experiences that can either enhance their ability to cope in a healthy manner or lead them to succumb to stress-related disorders. Such interventions can occur throughout life, but are particularly powerful during “windows of opportunity” such as fetal development, early childhood, and adolescence (Halfon et al., 2014). Understanding the molecular, cellular, and circuit mechanisms that underlie this dynamic process is a challenge for our field, and will require integration across levels of analysis. But it can begin with existing fundamental knowledge about “molecular organizers” that play a key role in neurodevelopment and lifelong plasticity. Glucocorticoids and growth factors represent examples of such molecular organizers that impact development, gene expression, and the epigenetic impact of the environment on the biology of stress and coping.
The central role of glucocorticoids and their receptors
Steroid hormones were recognized in the 1960s as having major action via epigenetic regulation of gene expression. Upon their cloning, the corticosteroid hormone receptors GR and MR were classified as ligand-dependent transcription factors that reside preferentially in the cytoplasm as part of a complex of proteins. Interaction with glucocorticoid ligands causes the receptors to shuttle to the nucleus to modulate rates of transcription of target genes via a range of complex mechanisms that control gene expression, either enhancing or inhibiting it depending on the target genes and the presence of various molecular partners (Weikum et al., 2017). While this transcriptional modulation endows glucocorticoids with a broad, ranging impact on cellular function, researchers have uncovered additional (nontranscriptional) cellular and molecular mechanisms through which glucocorticoids, in conjunction with other mediators, affect processes from the nucleus to the cell surface, including mitochondria, causing structural remodeling of neurons. These discoveries reveal the complexity of glucocorticoid interactions both genomically and nongenomically (Fig. 2). These effects range from rapid actions related to the negative feedback mechanisms described above, to circadian modulatory actions, to lifelong organizing actions due to their ability to cause stable epigenetic modifications.
The wide-ranging importance of glucocorticoid receptors has been demonstrated by a range of genetic manipulations from knockout to overexpression to more targeted manipulations aimed specifically at the brain or at particular brain regions. Brain-wide knockout of GR results in significant endocrine imbalance, with elevated levels of corticosteroids and changes in energy metabolism and body weight control that are associated with changes in hormones such as leptin and insulin (Kellendonk et al., 2002). More targeted ablations of GR in specific circuits result in a range of behavioral and function changes, typically involving both neuroendocrine and affective functions (Whirledge and DeFranco, 2018).
The converse and somewhat less invasive intervention is to increase the expression of GR or MR only in certain regions and cell types in the brain to determine the associated molecular and behavioral phenotype. A series of studies examined the consequences of GR overexpression using a calcium/calmodulin-dependent protein kinase II α promoter that selects for forebrain glutamatergic neurons (Wei et al., 2004, 2007, 2012; Hebda-Bauer et al., 2010). The adult phenotype of the GRov mouse was striking in that the animals appear more prone to anxiety-like and depression-like behaviors, but the states were also highly labile—mice were more likely to switch affective state in response to even low levels of drugs, be they anti-depressant drugs or drugs of abuse, and they would swing readily to the other behavioral extreme (Wei et al., 2004; Hebda-Bauer et al., 2010). Most importantly, using an inducible, tissue-specific genetic induction, these studies showed that the GRov phenotype was fully established before weaning and associated with lifelong alterations in gene expression in the hippocampus, including in glutamatergic, GABAergic, and calcium regulatory pathways. Induction of GR overexpression after weaning and throughout the life of the animal yielded neither the altered affective responses nor the great lability in emotional reactivity (Wei et al., 2012). By contrast, MR overexpression, while less well studied, results in a distinctive phenotype with less anxiety behavior (Rozeboom et al., 2007), consonant with the view that the GR–MR balance is critical in many cellular and behavioral functions (Joëls and de Kloet, 2017). Experiments using current technologies such as optogenetic manipulations and CRISPR-Cas9 are underway and should add further understanding to the role of these glucocorticoid receptors in ongoing regulation of affect and mood.
This body of genetic work along with research on the regulation of GR at the genomic, epigenetic, and gene expression levels establish this receptor as critical in the regulation of emotions and emotionality, not only basally but also in terms of dynamic reactivity to the environment, with social environment and early development playing a particularly powerful role (Turecki and Meaney, 2016).
Stress and affective disorders: reverse translation to animal models
Given the ongoing, powerful, and dynamic nature of stress biology described above, it is not surprising that dysregulation of the stress system and increased allostatic load are implicated in many psychiatric disorders. Indeed, affective disorders, including major depressive disorder (MDD), bipolar disorder, anxiety and panic disorders, and post-traumatic stress disorder (PTSD) can all be seen as stress disorders where key neural circuits that regulate stress reactivity are not functioning optimally. This dysregulation might include enhanced reactivity to threatening stimuli, decreased ability to terminate the stress response, and/or suboptimal coupling between internal affective states and external environment. This latter dysfunction can result in moods shifting in an extreme and seemingly random fashion in bipolar illness, or being “stuck” in a negative mode in major depression. Though heritable to various extents (ranging from 35% for MDD to >60% for bipolar disorder; Smoller and Finn, 2003; Geschwind and Flint, 2015), the nature of the vulnerability to these disorders relates to how the individual responds to the environment (Akil et al., 2018). Indeed, a recent major study on the genetics of depression (Wray et al., 2018) that examined ∼460,000 subjects concludes that “All humans carry lesser or greater numbers of genetic risk factors for major depression” and notes that the findings are consistent with the dysregulation of the HPA axis in depression. How these genetic influences play out depends on the fine-tuning and plasticity of the stress response by the individual's developmental trajectory and life experiences.
While the brain plays a key role in orchestrating and fine-tuning stress responsiveness, it is important to recall that the brain is also the target of changes throughout the body, which are a major type of proximal, ongoing, and sometimes toxic stress. This includes metabolic syndrome and insulin resistance, which, like major depression, have become a global burden and are often comorbid with depression. The physiological mechanisms underlying this brain–body cross talk are receiving increasing attention (Watson et al., 2018), and the complex interplay between early life stressors and metabolic factors is being analyzed as one of the many paths to depressive illness (Nasca et al., 2019). Other physiological factors that influence how the brain responds to stress include increased circulating levels of = glucocorticoids (e.g., in Cushing's disease), disrupted circadian rhythms, jet lag (Cho, 2001) and disrupted sleep, a sedentary life style, and others.
Demonstrating the impact of toxic stress and depression on the human brain has involved both structural and functional fMRI, which reveal shrinkage of the hippocampus. Postmortem human studies have not only confirmed the toxic effects of major depression on the brain but have also revealed the breadth and complexity of these neural perturbations at the molecular, cellular, and circuitry levels. This work is consistent with the presence of significant dysregulation in the stress circuitry, especially in the hippocampus (López et al., 1998; Webster et al., 2002; Klok et al., 2011; Medina et al., 2013). But it also reveals dynamic changes in many other functions important for motivational and affective functions. For example, the expression of circadian genes is highly disrupted in major depression, along with hundreds of other genes that are modulated in a circadian fashion. Thus, while the circadian expression signature of the control brain can pinpoint the time of death within an hour of its actual occurrence, the pattern in depressed brains is time shifted, making it impossible to match the circadian signature of the brain with the time of death (Li et al., 2013; Bunney et al., 2015). The widespread brain dysregulation revealed by these studies might be either the cause or the consequence of the disease process. Regardless, it likely contributes to the progressive disruption in physiology, affective and cognitive states, and behavioral functioning that are the hallmark of severe mood disorders.
Further underscoring the insidious nature of this stress disorder is the dysregulation of several gene families relating to cellular development, cell repair, and growth factors. For example, the FGF family was discovered to be dysregulated in major depression (Evans et al., 2004; Aurbach et al., 2015). Reverse translation studies reveal the close ties of this family not only to anxiety and depression behaviors, but also to the interplay with stress, emotional responsiveness, and vulnerability or resilience in response to life stressors.
In particular, a specific member of the FGF family, FGF2, has been shown to function as an “endogenous antidepressant.” Hippocampal and frontal cortical levels of FGF2 are low in human depression, and they are also decreased in rodents following repeated social stress and have been shown to modulate the HPA axis via GR (Turner et al., 2008a,b, 2016; Salmaso et al., 2016). Exogenously administered FGF2 functions as an antidepressant in animal tests of depressive behavior, and neonatally administered FGF2 functions as a resilience factor, protecting animals against social defeat stress, enhancing extinction of learned fear, and decreasing anxiety behavior in animals genetically bred for high vulnerability to stress (Turner et al., 2008,b, 2011, 2012; Perez et al., 2009; Prater et al., 2017). In contrast, FGF9, which is elevated in depressed brain, functions as a vulnerability factor, which is increased by chronic stress in animal models (Aurbach et al., 2015), and its selective inhibition in the hippocampus diminishes anxiety behavior. Remarkably, resilience-inducing FGF2 treatment during early life results in epigenetic changes to GR in the hippocampus, increasing its association with a repressive histone, H3K9Me3 (Chaudhury et al., 2014), once again illustrating the role of both glucocorticoids and growth factors as organizing molecules that function during development in fine-tuning responsiveness to stress throughout the individual's life.
Overall, the combination of human neuroimaging studies and postmortem analyses reveals that stress-related affective disorders have a broader impact on the brain than we had previously estimated—they affect connectivity across multiple brain regions, and they impact multiple circuits, cell types, and molecular players. This is likely secondary to the unfolding of a lifelong process where mechanisms of adaptive neuroplasticity prove inadequate to compensate for the ongoing stress. This failure has neural and behavioral consequences, which in turn demand further and further efforts at adaptation and compensation, until these mechanisms fail, and this is expressed as a devastating disorder.
Brain health and the broader social context
The picture that emerges from neurobiological studies of depression, coupled with epidemiological analyses, highlights the interplay between stress biology and general health, which is strongly influenced by social context. This involves the whole life course, where poverty, as well as other forms of early life adversity such as abuse and neglect, increase disproportionately the risk for diabetes, depression, cardiovascular disease, substance abuse, and later dementia, and thus increase human misery and the health care cost burden (Shonkoff et al., 2009; McEwen and McEwen, 2017). Moreover, the hippocampus and interconnected brain regions such as amygdala and prefrontal cortex show effects accompanying these conditions on structure and function, examples of which are summarized in Table 2, illustrating the association between brain and body health.
The interplay between social context and stress biology brings us back to the broad concept of allostatic load, the impact of experience, and the concept of the “exposome” (Miller and Jones, 2014), which reflects how the totality of the social and physical environment shapes the brain and its ability to function both cognitively and affectively. The sum total of experiences can become restrictive and undermine optimal functioning (https://macses.ucsf.edu/research/psychosocial/selfesteem.php). But by the same token, the ability to adapt, cope, and remodel the brain in an ongoing way also provides opportunities for positive change. Indeed, numerous studies have revealed the positive impact of activities such as regular exercise and intense learning in improving the volume and activity of the hippocampus and in mediating greater resilience to stress (Table 2).
Future directions: the neurobiology of stress as the basic science of affective disorders
Given the staggering burden of affective disorders, there is great interest in advancing our understanding of their underlying causes and translating this knowledge into better treatments. It is our view that the neurobiology of stress represents the basic biology of affective disorders. While we have accumulated an impressive body of knowledge in the last 50 years about stress biology, we have barely scratched the surface. For cancer research to make progress and begin to contemplate the possibility of precision medicine, it was essential to delve into the fundamental biology of cell growth, cell death, and cell signaling. In turn, the aberrations seen under pathological conditions of cancer pointed the way to new mechanisms and led to exciting fundamental discoveries. By the same token, it is essential that we achieve much greater depth, mechanistic understanding, and specificity in our field if we are to make a dent in the treatment and prevention of stress disorders. While the interest in precision medicine in neuroscience is high, the path remains unclear, as strongly predictive genetic markers and other biomarkers are not currently in hand. Confronting the heterogeneity of these diseases is a necessary first step. A better delineation of the many paths to affective disorders and how they might interface with different biological and clinical outcomes is essential.
This thinking should inform not only our human studies but also our attempts at animal models. In some cases, the mere recognition that the biology of stress matters in understanding the action of putative drugs is helpful (Fitzgerald et al., 2019). In other cases, more sophisticated tests need to be developed to account for the complex interplay of factors and experience in capturing key features of a particular subtype of affective illness and addressing it. Thus, a thoughtful and systematic approach to translation and reverse translation strategies is essential for making significant progress in treatment and prevention of stress-related disorders (Bale et al., 2019).
In sum, our view of the biology of stress underscores its ongoing, cumulative, and adaptive nature. While this process can become dysregulated, leading to a range of affective, stress-related disorders, it also offers many opportunities for retuning, not only through medical approaches, but also through psychosocial strategies, as well as through a greater emphasis on general health and fitness as a means of achieving resilience. Focusing upon interventions to prevent or to ameliorate the effects of early life adversity can have a disproportionately large positive influence on individual and population health over the life course.
Footnotes
Recent research referred to in this report was supported by National Institutes of Health (NIH) Grant RO1-MH41256 (to B.S.M.); The Hope for Depression Research Foundation (B.S.M., H.A.); NIH/National Institute on Drug Abuse Grant U01-DA-043098 (to H.A.); NIH/National Institute of Mental Health Grant R01-MH-104261 (to H.A.); Office of Naval Research Grants N00014-12-1-0366 and 00014-19-1-2149 (to H.A.); and the Pritzker Neuropsychiatric Research Consortium (H.A.).
The authors declare no competing financial interests.
- Correspondence should be addressed to Huda Akil at akil{at}umich.edu